COVID-19, myocardial edema and dexamethasone

Area of Science:

• Virology
• Immunology
• Cardiology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, leading to high mortality, often due to acute respiratory distress syndrome (ARDS).
• Severe COVID-19 patients frequently experience multi-organ injury, including cardiac, kidney, and liver damage, correlating with poor prognosis.
• Current treatments include Remdesivir (FDA-approved antiviral) and Glucocorticoids (GCs) for cytokine storm and respiratory failure.

Discussion:

• Glucocorticoids are known to stabilize the vascular endothelial barrier and reduce tissue edema.
• This vascular stabilizing effect may be particularly beneficial in mitigating myocardial injury in COVID-19 patients.
• The reduction in vascular permeability could be a significant factor in improving outcomes for hospitalized severe COVID-19 cases.

Key Insights:

• Glucocorticoids' ability to decrease vascular permeability may offer a novel therapeutic avenue.
• This mechanism could contribute to reduced mortality in severe COVID-19, especially with cardiac involvement.
• Further research is warranted to confirm the specific impact of GCs on myocardial injury and overall mortality.

Outlook:

• Investigating the precise mechanisms by which GCs impact myocardial injury in COVID-19.
• Evaluating the synergistic effects of GCs with other COVID-19 therapies.
• Exploring the potential for GCs as a standard-of-care component for severe COVID-19 patients with cardiac complications.